People with psychotic disorders are the most vulnerable to cannabis adverse health outcomes: a study in WA State, USA
- 16 January 2026
- journal article
- research article
- Published by Springer Nature in Community Mental Health Journal
- Vol. 62 (5) , 889-895
Abstract
Cannabis use has been shown to negatively impact the management and prognosis of psychotic disorders. Little is known about the broader health impacts of cannabis use in this population. This study compares cannabis-related negative health outcomes among individuals with a diagnosis of a psychotic disorder to those with other mental health (MH) diagnoses or no MH diagnosis. Data came from International Cannabis Policy Study (2020–2023). Respondents were 4,144 Washington State individuals aged 16–65, who consumed cannabis in the last 12 months. Three groups were compared for cannabis use negative health events: lifetime diagnoses of psychotic disorders, other MH and no MH diagnoses. Logistic regressions were used in the analysis. People with psychotic disorders were more likely to report adverse events from their cannabis use and to pursue medical attention than consumers with other MH or no MH diagnoses (p < .001.) They had higher likelihood of nausea/vomiting, heart or blood pressure problems, fainting, acute psychosis or hallucinations, flashbacks, Cannabis Hyperemesis Syndrome, and positive screening for high-risk cannabis use than consumers with other MH or no MH diagnoses. Individuals with psychotic disorder experience more adverse health events from cannabis, including events not associated with exacerbation of their disorders. These findings highlight the need to develop focused clinical interventions and awareness campaigns to address elevated risks of cannabis use among this vulnerable population.Keywords
Funding Information
- Washington State Legislature (ESSB 5187 (2023))
- Washington State Legislature (ESSB 5187 (2023))
- Washington State Legislature (ESSB 5187 (2023))
- University of Washington’s Cannabis Dedicated Account
- Canadian Institutes of Health Research (CIHR) Project Bridge Grant (PJT-153342)
This publication has 15 references indexed in Scilit:
- Threaten, Distract, and Discredit: Cannabis Industry Rhetoric to Defeat Regulation of High-THC Cannabis Products in Washington StateJournal of Studies on Alcohol and Drugs, 2024
- Trends in Substance-Related Visits Among Youth to US Children’s Hospitals, 2016–2021: An Analysis of the Pediatric Health Information System DatabaseJournal of Adolescent Health, 2024
- Adverse outcomes of cannabis use in Canada, before and after legalisation of non-medical cannabis: cross-sectional analysis of the International Cannabis Policy StudyBMJ Open, 2024
- Young adults with psychosis: Intentions for cannabis reduction and cessation based on theory of planned behavior.Psychiatric Rehabilitation Journal, 2022
- Changes in Emergency Department Visits for Cannabis Hyperemesis Syndrome Following Recreational Cannabis Legalization and Subsequent Commercialization in Ontario, CanadaJAMA Network Open, 2022
- Cannabis and mental health: Prevalence of use and modes of cannabis administration by mental health statusAddictive Behaviors, 2021
- Evaluating the impacts of cannabis legalization: The International Cannabis Policy StudyInternational Journal of Drug Policy, 2020
- Prevalence and correlates of cannabis poisoning diagnosis in a national emergency department sampleDrug and Alcohol Dependence, 2019
- Cannabis Use Is Associated With Increased Psychotic Symptoms and Poorer Psychosocial Functioning in First-Episode Psychosis: A Report From the UK National EDEN StudySchizophrenia Bulletin, 2015
- Social Functioning Trajectories of Young First-Episode Psychosis Patients with and without Cannabis Misuse: A 30-Month Follow-Up StudyPLOS ONE, 2015